Overview

Evaluating Etanercept Use in Patients With Moderate to Severe Rheumatoid Arthritis Who Have Lost Response to Adalimumab

Status:
Terminated
Trial end date:
2015-06-11
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of etanercept in adults with moderate-to-severe rheumatoid arthritis (RA) who did not respond to or lost a satisfactory response to adalimumab when used as their first biologic agent.
Phase:
Phase 4
Details
Lead Sponsor:
Amgen
Treatments:
Adalimumab
Etanercept
Methotrexate